M
Mauro Delorenzi
Researcher at Swiss Institute of Bioinformatics
Publications - 250
Citations - 34394
Mauro Delorenzi is an academic researcher from Swiss Institute of Bioinformatics. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 72, co-authored 242 publications receiving 29291 citations. Previous affiliations of Mauro Delorenzi include University of Zurich & University Hospital of Lausanne.
Papers
More filters
Journal ArticleDOI
The consensus molecular subtypes of colorectal cancer
Justin Guinney,Rodrigo Dienstmann,Rodrigo Dienstmann,Xingwu Wang,Xingwu Wang,Aurélien de Reyniès,Andreas Schlicker,Charlotte Soneson,Laetitia Marisa,Paul Roepman,Gift Nyamundanda,Paolo Angelino,Brian M. Bot,Jeffrey S. Morris,Iris Simon,Sarah Gerster,Evelyn Fessler,Felipe De Sousa E Melo,Edoardo Missiaglia,Hena R. Ramay,David Barras,Krisztian Homicsko,Dipen M. Maru,Ganiraju C. Manyam,Bradley M. Broom,Valérie Boige,Beatriz Perez-Villamil,Ted Laderas,Ramon Salazar,Joe W. Gray,Douglas Hanahan,Josep Tabernero,René Bernards,Stephen H. Friend,Pierre Laurent-Puig,Jan Paul Medema,Anguraj Sadanandam,Lodewyk F. A. Wessels,Mauro Delorenzi,Mauro Delorenzi,Scott Kopetz,Louis Vermeulen,Sabine Tejpar +42 more
TL;DR: An international consortium dedicated to large-scale data sharing and analytics across expert groups is formed, showing marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features.
Journal ArticleDOI
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso,Miriam Martini,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi,Josep Tabernero,Teresa Macarulla,Frédéric Di Fiore,Alice Gangloff,Fortunato Ciardiello,Per Pfeiffer,Camilla Qvortrup,Tine Plato Hansen,Eric Van Cutsem,Hubert Piessevaux,Diether Lambrechts,Mauro Delorenzi,Mauro Delorenzi,Sabine Tejpar +37 more
TL;DR: This is the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era and confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA population response rates confirmed that.
Journal ArticleDOI
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
Christos Sotiriou,Pratyaksha Wirapati,Sherene Loi,Adrian L. Harris,Steve Fox,Johanna Smeds,Hans Nordgren,Pierre Farmer,Viviane Praz,Benjamin Haibe-Kains,Christine Desmedt,Denis Larsimont,Fatima Cardoso,Hans Peterse,Dimitry S.A. Nuyten,Marc Buyse,Marc J. van de Vijver,Jonas Bergh,Martine Piccart,Mauro Delorenzi +19 more
TL;DR: Gene expression grade index appeared to reclassify patients with histologic grade 2 tumors into two groups with high versus low risks of recurrence, which may improve the accuracy of tumor grading and thus its prognostic value.
Journal ArticleDOI
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fatima Cardoso,Laura J. van't Veer,Jan Bogaerts,Leen Slaets,Giuseppe Viale,Suzette Delaloge,Jean-Yves Pierga,Etienne Brain,Sylvain Causeret,Mauro Delorenzi,Annuska M. Glas,Vassilis Golfinopoulos,Theodora Goulioti,Susan J. Knox,Erika Matos,Bart Meulemans,Peter A. Neijenhuis,Ulrike Nitz,Rodolfo Passalacqua,Peter M. Ravdin,Isabel T. Rubio,Mahasti Saghatchian,Tineke J. Smilde,Christos Sotiriou,Lisette Stork,Carolyn Straehle,Geraldine A. Thomas,Alastair M. Thompson,Jacobus J.M. van der Hoeven,Peter Vuylsteke,René Bernards,Konstantinos Tryfonidis,Emiel J. Th. Rutgers,Martine Piccart +33 more
TL;DR: Among women with early-stage breast cancer who were at high clinical risk and low genomic risk for recurrence, the receipt of no chemotherapy on the basis of the 70-gene signature led to a 5-year rate of survival without distant metastasis that was 1.5 percentage points lower than the rate with chemotherapy.
Journal ArticleDOI
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
Marc Buyse,Sherene Loi,Laura J. van't Veer,Giuseppe Viale,Mauro Delorenzi,Annuska M. Glas,Mahasti Saghatchian d'Assignies,Jonas Bergh,Rosette Lidereau,Paul Ellis,Adrian L. Harris,Jan Bogaerts,Patrick Therasse,Arno Floore,Mohamed Amakrane,Fanny Piette,Emiel J. Th. Rutgers,Christos Sotiriou,Fatima Cardoso,Martine Piccart +19 more
TL;DR: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer and outperformed the clinicopathological risk assessment in predicting all endpoints.